Stock Track | Erasca, Inc. Plummets 5.05% in Pre-Market on Clinical Trial Safety Concerns and Patent Litigation

Stock Track

Apr 29

Erasca, Inc. (ERAS) shares plummeted 5.05% in pre-market trading on Wednesday, continuing the downward pressure from recent clinical setbacks and legal challenges.

The decline follows Tuesday's 48% plunge after the cancer drug developer reported a patient death in a clinical trial. A 66-year-old man experienced severe lung inflammation approximately one month after starting Erasca's experimental therapy and passed away after treatment was halted. This contradicts the company's previous statements that its therapy was generally well-tolerated with mostly low-grade side effects.

Additionally, Erasca received a cease-and-desist letter from competitor Revolution Medicines Inc. on Monday, alleging that Erasca's cancer therapy infringes on certain elements of a Revolution Medicines patent. Analysts note that these developments have raised questions about the evolving safety profile and created near-term pressure on the stock until greater clarity emerges on both the clinical trial outcomes and the litigation trajectory.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1157464198"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1157464198\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1157464198?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-29 21:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157464198","market":"sg","top_or_hot":-1,"title":"Stock Track | Erasca, Inc. Plummets 5.05% in Pre-Market on Clinical Trial Safety Concerns and Patent Litigation","media":"Stock Track","content":"<p>Erasca, Inc. (ERAS) shares plummeted 5.05% in pre-market trading on Wednesday, continuing the downward pressure from recent clinical setbacks and legal challenges.</p><p>The decline follows Tuesday's 48% plunge after the cancer drug developer reported a patient death in a clinical trial. A 66-year-old man experienced severe lung inflammation approximately one month after starting Erasca's experimental therapy and passed away after treatment was halted. This contradicts the company's previous statements that its therapy was generally well-tolerated with mostly low-grade side effects.</p><p>Additionally, Erasca received a cease-and-desist letter from competitor Revolution Medicines Inc. on Monday, alleging that Erasca's cancer therapy infringes on certain elements of a Revolution Medicines patent. Analysts note that these developments have raised questions about the evolving safety profile and created near-term pressure on the stock until greater clarity emerges on both the clinical trial outcomes and the litigation trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Erasca, Inc. Plummets 5.05% in Pre-Market on Clinical Trial Safety Concerns and Patent Litigation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Erasca, Inc. Plummets 5.05% in Pre-Market on Clinical Trial Safety Concerns and Patent Litigation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-29 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Erasca, Inc. (ERAS) shares plummeted 5.05% in pre-market trading on Wednesday, continuing the downward pressure from recent clinical setbacks and legal challenges.</p><p>The decline follows Tuesday's 48% plunge after the cancer drug developer reported a patient death in a clinical trial. A 66-year-old man experienced severe lung inflammation approximately one month after starting Erasca's experimental therapy and passed away after treatment was halted. This contradicts the company's previous statements that its therapy was generally well-tolerated with mostly low-grade side effects.</p><p>Additionally, Erasca received a cease-and-desist letter from competitor Revolution Medicines Inc. on Monday, alleging that Erasca's cancer therapy infringes on certain elements of a Revolution Medicines patent. Analysts note that these developments have raised questions about the evolving safety profile and created near-term pressure on the stock until greater clarity emerges on both the clinical trial outcomes and the litigation trajectory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ERAS","symbol_name":"Erasca, INC.","start_time":0,"source_url":"","article_id":"1157464198","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157464198","pubTimestamp":1777469586,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Erasca, Inc. (ERAS) shares plummeted 5.05% in pre-market trading on Wednesday, continuing the downward pressure from recent clinical setbacks and legal challenges.The decline follows Tuesday's 48%...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ERAS":"Erasca, INC."},"translate_title":"个股追踪|Erasca，Inc.盘前暴跌5.05%因临床试验安全担忧和专利诉讼","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ERAS":1},"content_text":"Erasca, Inc. (ERAS) shares plummeted 5.05% in pre-market trading on Wednesday, continuing the downward pressure from recent clinical setbacks and legal challenges.The decline follows Tuesday's 48% plunge after the cancer drug developer reported a patient death in a clinical trial. A 66-year-old man experienced severe lung inflammation approximately one month after starting Erasca's experimental therapy and passed away after treatment was halted. This contradicts the company's previous statements that its therapy was generally well-tolerated with mostly low-grade side effects.Additionally, Erasca received a cease-and-desist letter from competitor Revolution Medicines Inc. on Monday, alleging that Erasca's cancer therapy infringes on certain elements of a Revolution Medicines patent. Analysts note that these developments have raised questions about the evolving safety profile and created near-term pressure on the stock until greater clarity emerges on both the clinical trial outcomes and the litigation trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}